Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Oct;85(8):1219–1225. doi: 10.1054/bjoc.2001.2024

Nucleolar damage correlates with neurotoxicity induced by different platinum drugs

M J McKeage 1, T Hsu 1, D Screnci 1, G Haddad 1, B C Baguley 2
PMCID: PMC2375155  PMID: 11710838

Abstract

Platinum-based drugs are very useful in cancer therapy but are associated with neurotoxicity in the clinic. To investigate the mechanism of neurotoxicity, dorsal root ganglia of rats treated with various platinum drugs were studied. Cell body, nuclear and nucleolar dimensions of dorsal root ganglia sensory nerve cells were measured to determine morphological toxicity. Sensory nerve conduction velocity was measured to determine functional toxicity. After a single dose of oxaliplatin (10 mg kg−1), no significant change in nuclear and cell body diameter was seen but decreased nucleolar size was apparent within a few hours of treatment. Changes in nucleolar size were maximal at 24 hours, recovered very slowly and showed a non-linear dependence on oxaliplatin dose (r2= 0.99). Functional toxicity was delayed in onset until 14 days after a single dose of oxaliplatin but eventually recovered 3 months after treatment. Multiple doses of cisplatin, carboplatin, oxaliplatin, R, R -ormaplatin and S, S -ormaplatin were also associated with time-dependent reduction in nucleolar size. A linear correlation was obtained between the rate of change in nucleolar size during multiple dose treatment with the series of platinum drugs and the time taken for the development of altered sensory nerve conduction velocity (r2= 0.86;P< 0.024). Damage to the nucleolus of ganglionic sensory neurons is therefore linked to the neurotoxicity of platinum-based drugs, possibly through mechanisms resulting in the inhibition of rRNA synthesis. © 2001 Cancer Research Campaign  http://www.bjcancer.com

Keywords: platinum drugs, cancer chemotherapy, neurotoxicity, dorsal root ganglia, nucleolus

Full Text

The Full Text of this article is available as a PDF (108.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brasch K. Drug and metabolite-induced perturbations in nuclear structure and function: a review. Biochem Cell Biol. 1990 Feb;68(2):408–426. doi: 10.1139/o90-059. [DOI] [PubMed] [Google Scholar]
  2. Cavaletti G., Fabbrica D., Minoia C., Frattola L., Tredici G. Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol. 1998 Apr;9(4):443–447. doi: 10.1023/a:1008231925889. [DOI] [PubMed] [Google Scholar]
  3. Cavaletti G., Tredici G., Marmiroli P., Petruccioli M. G., Barajon I., Fabbrica D. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol. 1992;84(4):364–371. doi: 10.1007/BF00227662. [DOI] [PubMed] [Google Scholar]
  4. Cece R., Petruccioli M. G., Cavaletti G., Barajon I., Tredici G. An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. Histol Histopathol. 1995 Oct;10(4):837–845. [PubMed] [Google Scholar]
  5. Cece R., Petruccioli M. G., Pizzini G., Cavaletti G., Tredici G. Ultrastructural aspects of DRG satellite cell involvement in experimental cisplatin neuronopathy. J Submicrosc Cytol Pathol. 1995 Oct;27(4):417–425. [PubMed] [Google Scholar]
  6. Coggeshall R. E., La Forte R., Klein C. M. Calibration of methods for determining numbers of dorsal root ganglion cells. J Neurosci Methods. 1990 Dec;35(3):187–194. doi: 10.1016/0165-0270(90)90123-w. [DOI] [PubMed] [Google Scholar]
  7. Einhorn E. H. Testicular cancer: an oncological success story. Clin Cancer Res. 1997 Dec;3(12 Pt 2):2630–2632. [PubMed] [Google Scholar]
  8. Extra J. M., Marty M., Brienza S., Misset J. L. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol. 1998 Apr;25(2 Suppl 5):13–22. [PubMed] [Google Scholar]
  9. Gregg R. W., Molepo J. M., Monpetit V. J., Mikael N. Z., Redmond D., Gadia M., Stewart D. J. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol. 1992 May;10(5):795–803. doi: 10.1200/JCO.1992.10.5.795. [DOI] [PubMed] [Google Scholar]
  10. Harder H. C., Rosenberg B. Inhibitory effects of anti-tumor platinum compounds on DNA, RNA and protein syntheses in mammalian cells in virtro. Int J Cancer. 1970 Sep 15;6(2):207–216. doi: 10.1002/ijc.2910060207. [DOI] [PubMed] [Google Scholar]
  11. Holmes J., Stanko J., Varchenko M., Ding H., Madden V. J., Bagnell C. R., Wyrick S. D., Chaney S. G. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci. 1998 Dec;46(2):342–351. doi: 10.1006/toxs.1998.2558. [DOI] [PubMed] [Google Scholar]
  12. Ivanov A. I., Christodoulou J., Parkinson J. A., Barnham K. J., Tucker A., Woodrow J., Sadler P. J. Cisplatin binding sites on human albumin. J Biol Chem. 1998 Jun 12;273(24):14721–14730. doi: 10.1074/jbc.273.24.14721. [DOI] [PubMed] [Google Scholar]
  13. Jamieson E. R., Lippard S. J. Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev. 1999 Sep 8;99(9):2467–2498. doi: 10.1021/cr980421n. [DOI] [PubMed] [Google Scholar]
  14. Jones T. W., Chopra S., Kaufman J. S., Flamenbaum W., Trump B. F. Cis-diamminedichloroplatinum (II)-induced acute renal failure in the rat. Correlation of structural and functional alterations. Lab Invest. 1985 Apr;52(4):363–374. [PubMed] [Google Scholar]
  15. Jordan P., Carmo-Fonseca M. Cisplatin inhibits synthesis of ribosomal RNA in vivo. Nucleic Acids Res. 1998 Jun 15;26(12):2831–2836. doi: 10.1093/nar/26.12.2831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lehane D., Winston A., Gray R., Daskal Y. The effect of diuretic pre-treatment on clinical, morphological and ultrastructural cis-platinum induced nephrotoxicity. Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1393–1399. doi: 10.1016/0360-3016(79)90677-1. [DOI] [PubMed] [Google Scholar]
  17. Leibbrandt M. E., Wolfgang G. H., Metz A. L., Ozobia A. A., Haskins J. R. Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int. 1995 Sep;48(3):761–770. doi: 10.1038/ki.1995.348. [DOI] [PubMed] [Google Scholar]
  18. Lemaire M. A., Schwartz A., Rahmouni A. R., Leng M. Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum (II) and DNA. Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1982–1985. doi: 10.1073/pnas.88.5.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. McKeage M. J., Boxall F. E., Jones M., Harrap K. R. Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat. Cancer Res. 1994 Feb 1;54(3):629–631. [PubMed] [Google Scholar]
  20. Misset J. L. Oxaliplatin in practice. Br J Cancer. 1998 Jun;77 (Suppl 4):4–7. doi: 10.1038/bjc.1998.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Müller L. J., Gerritsen van der Hoop R., Moorer-van Delft C. M., Gispen W. H., Roubos E. W. Morphological and electrophysiological study of the effects of cisplatin and ORG.2766 on rat spinal ganglion neurons. Cancer Res. 1990 Apr 15;50(8):2437–2442. [PubMed] [Google Scholar]
  22. Ozols R. F., Corden B. J., Jacob J., Wesley M. N., Ostchega Y., Young R. C. High-dose cisplatin in hypertonic saline. Ann Intern Med. 1984 Jan;100(1):19–24. doi: 10.7326/0003-4819-100-1-19. [DOI] [PubMed] [Google Scholar]
  23. Poirier M. C., Reed E., Litterst C. L., Katz D., Gupta-Burt S. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res. 1992 Jan 1;52(1):149–153. [PubMed] [Google Scholar]
  24. Schilder R. J., LaCreta F. P., Perez R. P., Johnson S. W., Brennan J. M., Rogatko A., Nash S., McAleer C., Hamilton T. C., Roby D. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res. 1994 Feb 1;54(3):709–717. [PubMed] [Google Scholar]
  25. Screnci D., Er H. M., Hambley T. W., Galettis P., Brouwer W., McKeage M. J. Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. Br J Cancer. 1997;76(4):502–510. doi: 10.1038/bjc.1997.416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Screnci D., McKeage M. J., Galettis P., Hambley T. W., Palmer B. D., Baguley B. C. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer. 2000 Feb;82(4):966–972. doi: 10.1054/bjoc.1999.1026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Shaw P. J., Jordan E. G. The nucleolus. Annu Rev Cell Dev Biol. 1995;11:93–121. doi: 10.1146/annurev.cb.11.110195.000521. [DOI] [PubMed] [Google Scholar]
  28. Stacchiotti A., Rezzani R., Rodella L., Ventura R. G. Lysosomal changes in rat spinal ganglia neurons after prolonged treatment with cisplatin. Acta Anat (Basel) 1995;153(3):236–242. doi: 10.1159/000147738. [DOI] [PubMed] [Google Scholar]
  29. Thomas G. M. Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy. N Engl J Med. 1999 Apr 15;340(15):1198–1200. doi: 10.1056/NEJM199904153401509. [DOI] [PubMed] [Google Scholar]
  30. Thompson S. W., Davis L. E., Kornfeld M., Hilgers R. D., Standefer J. C. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer. 1984 Oct 1;54(7):1269–1275. doi: 10.1002/1097-0142(19841001)54:7<1269::aid-cncr2820540707>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  31. Tomiwa K., Nolan C., Cavanagh J. B. The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol. 1986;69(3-4):295–308. doi: 10.1007/BF00688308. [DOI] [PubMed] [Google Scholar]
  32. Treiber D. K., Zhai X., Jantzen H. M., Essigmann J. M. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5672–5676. doi: 10.1073/pnas.91.12.5672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Vichi P., Coin F., Renaud J. P., Vermeulen W., Hoeijmakers J. H., Moras D., Egly J. M. Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP. EMBO J. 1997 Dec 15;16(24):7444–7456. doi: 10.1093/emboj/16.24.7444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Zhai X., Beckmann H., Jantzen H. M., Essigmann J. M. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. Biochemistry. 1998 Nov 17;37(46):16307–16315. doi: 10.1021/bi981708h. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES